Search results
Three US Stocks Estimated To Be Trading Below Their Intrinsic Values In July 2024
Simply Wall St. via Yahoo Singapore Finance· 3 weeks agoAmidst a turbulent period for major indices like the Nasdaq and S&P 500, marked by tech sell-offs...
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Zacks via Yahoo Singapore Finance· 3 weeks agoThe Invesco Biotechnology & Genome ETF (PBE) made its debut on 06/23/2005, and is a smart beta...
Here’s Why Parnassus Value Equity Fund Sold BioMarin Pharmaceutical (BMRN)
Insider Monkey via Yahoo Singapore Finance· 1 month agoParnassus Investments, an investment management company, released the “Parnassus Value Equity Fund”...
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 41% Below Their Intrinsic Value Estimate
Simply Wall St. via Yahoo Singapore Finance· 1 month agoKey Insights BioMarin Pharmaceutical's estimated fair value is US$142 based on 2 Stage Free Cash...
Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock?
Zacks via Yahoo Singapore Finance· 1 month agoMirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being...
ETFs in Focus on the Upcoming S&P 500 Shake-Up
Zacks via Yahoo Singapore Finance· 2 months agoThe popular S&P Dow Jones Indices are set to get the customary new look this month. Every year, on the third Friday of June, the S&P 500, S&P MidCap 400...
BioMarin Pharmaceutical (NASDAQ:BMRN) shareholders have endured a 15% loss from investing in the...
Simply Wall St. via Yahoo Singapore Finance· 2 months agoIt's easy to match the overall market return by buying an index fund. Active investors aim to buy...
BioMarin (BMRN) Down 7.6% Since Last Earnings Report: Can It Rebound?
Zacks via Yahoo Singapore Finance· 2 months agoIt has been about a month since the last earnings report for BioMarin Pharmaceutical (BMRN). Shares...
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
Zacks via Yahoo Singapore Finance· 3 months agoFor Immediate Release Chicago, IL – May 7, 2024 – Today, Zacks Equity Research discusses BioMarin...
Insider Sale: EVP, Chief Commercial Officer Jeffrey Ajer Sells 5,000 Shares of Biomarin ...
GuruFocus.com via Yahoo Singapore Finance· 3 months agoOn May 2, 2024, Jeffrey Ajer, the Executive Vice President and Chief Commercial Officer of Biomarin...